Results 221 to 230 of about 181,689 (337)

The management of severe Crohn’s disease [PDF]

, 2001
Miles Parkes, D P Jewell
openalex   +1 more source

Evidence for a Modulatory Effect of a 12‐Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof‐of‐Principle Study

Molecular Nutrition &Food Research, EarlyView.
This study investigated how pomegranate juice affects inflammation in patients with inflammatory bowel disease who are currently in remission. After 12 weeks of drinking pomegranate juice, patients showed reduced markers of intestinal inflammation.
Ilaria Minato, Pedro Mena, Luigi Ricciardiello, Eleonora Scaioli, Andrea Belluzzi, Enrica Rotondo, Eleonora Derlindati, Barbara Montanini, Costanza Michelini, Nicole Tosi, Vicente Agullò Garcià, Gianfranco Picone, Carlo Mengucci, Sara Dobani, Paloma Salamanca, Alice Rosi, Margherita Dall'Asta, Letizia Bresciani, Claudio Curti, Enzo Spisni, Alessandra Dei Cas, Alessandra Bordoni, Francisco A. Tomás‐Barberán, Lynnette R. Ferguson, Daniele Del Rio, Francesca Danesi   +25 more
wiley   +1 more source

The Importance of Familial Clusterings in Crohn’s Disease [PDF]

, 2001
Herbert J. Van Kruiningen, Antoine Cortot, Jean–Frédéric Colombel   +2 more
openalex   +1 more source

A Nascent Nasal Phenomenon

JEADV Clinical Practice, EarlyView.
Amy Long, Claire Quigley, Lisa Murphy, Niamh Leonard, Julianne Clowry   +4 more
wiley   +1 more source

Development of dietetic staffing requirements for adult intestinal failure services using a best‐practice model

Nutrition in Clinical Practice, EarlyView.
Abstract Background The number of people diagnosed with chronic intestinal failure (CIF) worldwide is low. The condition is clinically complex to manage and resource intense. Guidance on best‐practice staffing levels is lacking. This paper proposes a methodology for determining dietetic staffing levels for adult CIF to estimate dietetic staffing levels
Sharon Carey, Brooke Chapman, Emma Osland   +2 more
wiley   +1 more source

BONES AND CROHN’S: SHOULD WE TREAT CROHN’S DISEASE PATIENTS WITH ALENDRONATE? [PDF]

, 2001
Laurence Bailen
openalex   +1 more source

Epidemiology and the cost burden of hospitalized pediatric‐onset inflammatory bowel disease in China: A national database study

Pediatric Investigation, EarlyView.
This study provides insights into the clinical characteristics and cost burden of pediatric‐onset inflammatory bowel disease (PIBD) and very early onset IBD (VEO‐IBD) in China. Hospitalizations for PIBD, particularly Crohn's disease, are increasing. Guidelines and health insurance policies can help mitigate the cost burden.
Xiaolu Nie, Jing Li, Hui Xu, Fang Hu, Xiaolin Ye, Mengmeng Yu, Guoshuang Feng, Yueping Zeng, Xin Ni, Jie Wu, Xiaoxia Peng, the Futang Research Center of Pediatric Development (FRCPD)   +11 more
wiley   +1 more source

GROWTH OF AN IBD CONTROVERSY: GROWTH HORMONE AND CROHN’S DISEASE [PDF]

, 2001
David G. Binion, Ramin Alemzadeh
openalex   +1 more source

Erythematous Papules and Plaques in an Infant Receiving Glucagon Therapy

JEADV Clinical Practice, EarlyView.
Sara Al Janahi, Alya Al‐Ali, Meera Al Adawi, Yusra S. Al Ali, Harish Bangalore   +4 more
wiley   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source